147 related articles for article (PubMed ID: 33815821)
1. Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma.
Tansir G; Rastogi S; Shamim SA; Barwad A
Future Sci OA; 2021 Jan; 7(4):FSO675. PubMed ID: 33815821
[TBL] [Abstract][Full Text] [Related]
2. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
[TBL] [Abstract][Full Text] [Related]
3. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
[TBL] [Abstract][Full Text] [Related]
4. Epithelioid Sarcoma-From Genetics to Clinical Practice.
Czarnecka AM; Sobczuk P; Kostrzanowski M; Spalek M; Chojnacka M; Szumera-Cieckiewicz A; Rutkowski P
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751241
[TBL] [Abstract][Full Text] [Related]
5. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
6. Epithelioid sarcoma and its outcome: a retrospective analysis from a tertiary care center in North India.
Kashyap D; Rastogi S; Garg V; Shrivastava S; Barwad A; Shamim SA; Hemrom A; Dhamija E; Bhoriwal S; Garg R
Future Sci OA; 2022 Oct; 8(9):FSO822. PubMed ID: 36788984
[TBL] [Abstract][Full Text] [Related]
7. Tazemetostat: First Approval.
Hoy SM
Drugs; 2020 Apr; 80(5):513-521. PubMed ID: 32166598
[TBL] [Abstract][Full Text] [Related]
8. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma.
Hornick JL; Dal Cin P; Fletcher CD
Am J Surg Pathol; 2009 Apr; 33(4):542-50. PubMed ID: 19033866
[TBL] [Abstract][Full Text] [Related]
9. Integrase Interactor 1 (INI1) Deficiency in a Lung Cancer Patient Presents Nonresponse to Immunotherapy and Tazemetostat: A Case Report.
Chen X; Wu J; Pang G; Wei S; Wang P
Cureus; 2023 Aug; 15(8):e42934. PubMed ID: 37667707
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma.
Xie L; Sun X; Xu J; Liang X; Liu K; Sun K; Yang R; Tang X; Guo W
BMC Cancer; 2024 Feb; 24(1):172. PubMed ID: 38310286
[TBL] [Abstract][Full Text] [Related]
11. Neck Epithelioid Sarcoma at an Unusual Location Mimicking Lymph Node Metastases of Nasopharyngeal Carcinoma: A Case Report.
El Ouardani S; Chibani H; Rezzoug F; Kharkhach A; Al Jarroudi O; Brahmi SA; Afqir S
Cureus; 2024 Mar; 16(3):e56484. PubMed ID: 38638767
[TBL] [Abstract][Full Text] [Related]
12. [Molecular genetics and immunophenotype of INI1/SMARCB in epithelioid sarcoma].
Li L; Xia Q; Rao Q; Liu B; Wu B; Shi S; Yu B; Zhang R; Lu Z; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Jun; 43(6):389-93. PubMed ID: 25208989
[TBL] [Abstract][Full Text] [Related]
13. Tazemetostat: EZH2 Inhibitor.
Straining R; Eighmy W
J Adv Pract Oncol; 2022 Mar; 13(2):158-163. PubMed ID: 35369397
[TBL] [Abstract][Full Text] [Related]
14. Targeting epigenetics in sarcomas through EZH2 inhibition.
Italiano A
J Hematol Oncol; 2020 Apr; 13(1):33. PubMed ID: 32264965
[TBL] [Abstract][Full Text] [Related]
15. Concurrent loss of INI1, PBRM1, and BRM expression in epithelioid sarcoma: implications for the cocontributions of multiple SWI/SNF complex members to pathogenesis.
Li L; Fan XS; Xia QY; Rao Q; Liu B; Yu B; Shi QL; Lu ZF; Zhou XJ
Hum Pathol; 2014 Nov; 45(11):2247-54. PubMed ID: 25200863
[TBL] [Abstract][Full Text] [Related]
16. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy.
Touati N; Schöffski P; Litière S; Judson I; Sleijfer S; van der Graaf WT; Italiano A; Isambert N; Gil T; Blay JY; Stark D; Brodowicz T; Marréaud S; Gronchi A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):448-454. PubMed ID: 29550245
[TBL] [Abstract][Full Text] [Related]
17. Ipsilateral breast metastasis after axillary dissection caused by epithelioid sarcoma: a case report and pathological investigation.
Chen L; Wang L; Zhang X; Yao M; Fu P
Diagn Pathol; 2019 Oct; 14(1):111. PubMed ID: 31615564
[TBL] [Abstract][Full Text] [Related]
18. Epithelioid sarcoma as the prototype for personalized therapy in soft tissue sarcoma.
Assi T; Rassy E; Nassereddine H; Farhat F; Kattan J
Per Med; 2020 Jul; 17(4):241-244. PubMed ID: 32589100
[No Abstract] [Full Text] [Related]
19. FNA of epithelioid sarcoma: Curie Institute experience and critical review of the literature.
Gajdzis P; Laé M; Klijanienko J
Cancer Cytopathol; 2018 Nov; 126(11):934-941. PubMed ID: 30291790
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of cytopathologic features of epithelioid sarcoma in a series of 7 uncommon cases with immunohistochemical results, including loss of INI1/SMARCB1 in two test cases.
Rekhi B; Singh N
Diagn Cytopathol; 2016 Jul; 44(7):636-42. PubMed ID: 27145123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
